Martin Cohen
Internal Medicine · Dallas, TXNPI 1871565309
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 101 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $621 and has fallen 94.4% since, to $35 in 2025.
Across 101 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi Pasteur Inc.$331
- AbbVie$233
- AstraZeneca$229
- Novo Nordisk$168
- Amgen$145
- Pfizer$135
- plus $711 from 17 others
What the payments were for
- Food & beverage$1,952100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi Pasteur Inc. | 6 | $331 |
| AbbVie(2 entities) | 17 | $233 |
| AstraZeneca | 10 | $229 |
| Novo Nordisk | 11 | $168 |
| Amgen | 8 | $145 |
| Pfizer | 8 | $135 |
| Johnson & Johnson | 5 | $131 |
| Astellas Pharma US Inc | 5 | $106 |
| GSK | 6 | $90 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $43 |
| Boehringer Ingelheim | 3 | $42 |
| Amarin Pharma, Inc. | 2 | $40 |
| Bayer | 3 | $39 |
| Boston Scientific | 2 | $35 |
| Biohaven Pharmaceuticals, Inc. | 1 | $26 |
| Lilly USA, LLC | 2 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| VBI Vaccine (delaware) Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Exact Sciences | 1 | $13 |
| Genentech USA, Inc. | 1 | $11 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$102
How this compares
$1,952 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 12 | $200 |
| Memantine Hcl | 11 | $171 |
| Levothyroxine Sodium | 18 | $150 |
| Amlodipine Besylate | 21 | $149 |
| Potassium Chloride | 11 | $122 |
| Allopurinol | 12 | $109 |
| Atenolol | 12 | $81 |
| Atorvastatin Calcium | 14 | $58 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Dallas
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Han SchmidlyDallas$465K
- Athica VatanapradithDallas$164K
- Nicholaos BellosDallas$113K
- Steven HeldDallas$65K
- Amit VermaDallas$53K
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Mohammed Al-NajjarEl Paso$586K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.